Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 38

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 issued an
aggregate of 400,951 shares of restricted common
stock for advisory and employee compensation, board compensation and accrued dividends for Series B Preferred shareholders, fair valued
at $491,324 with stock prices ranging from $1.19 through $1.46.

In
October, 2025, the Company issued an aggregate of 225,000
shares of restricted common stock related to a warrant exercise valued at $0.50
to $0.75  per share for total cash proceeds of $131,250.

 24 

ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

PetVivo
Holdings, Inc. (the “Company,” “PetVivo,” “we” or “us) is an emerging biomedical device company
focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company
has a pipeline of products for the treatment of animals. A portfolio of nineteen patents protects the Company’s biomaterials, products,
production processes, and methods of use. The Company began commercialization of its lead product Spryng® with OsteoCushion®
Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as
osteoarthritis in dogs and horses, in the second quarter of its fiscal year ended March 31, 2022.

The
Company was incorporated in March 2009 under Nevada law under a different name. The Company operates as one segment from its corporate
headquarters in Edina, Minnesota.

CURRENT
BUSINESS OPERATIONS

The
Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage
afflictions of companion animals such as dogs and horses. Most of our technology was developed for human biomedical applications, and
we intend to leverage the investments already expended in their development to commercialize treatments for horses and companion animals
in a capital and time-efficient way.

The
Company’s initial product, Spryng®, and its pipeline products are derived from proprietary biomaterials that simulate a body’s
cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions which incorporate such “tissue building
blocks” as collagen, elastin, and proteoglycans such as heparin. Since these are naturally-occurring in the body, we believe they
have an enhanced